5. Conclusions
glioblastoma, BrICS-LIT, necrosis
RECURRENCE, TUMOR PROGRESSION, NECROSIS, GLIOBLASTOMA, PATHOLOGY, TUMOR RECURRENCE
With a median time to follow-up of 20.3 months for censored patients, guiding escalated radiation dose to glioblastoma patients through spectroscopic MRI led to a median PFS of 16.6 months with a one-year incidence of recurrence from treatment of 30%, half that of standard therapy. These results are extremely encouraging and suggest the need for sMRI to be a part of standard clinical practice. While escalated radiation doses over larger treatment volumes show promising results towards improving survival, differentiating between true tumor recurrence and radiation-related necrosis even one year after completion of radiation therapy remains a challenge.By developing quantitative web applications such as BrICS-LIT, we have managed to segment lesions and calculate structured reporting scores for each patient during the follow-up phase of their treatment with the hope of more easily delineating recurrence. Through radiation map overlays, graphing lesion volumes for observable trends, and patient pathology reports, we present our methodology for calculating the tumor progression date. Through the quantitative data we have collected in BrICS-LIT, we plan to develop automated, optimized radiation treatment plans that operate at a voxel-level granularity, with the hope of delaying recurrence for as long as possible.